105
Views
2
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

The Multiple Sclerosis Depression Rating Scale

&
Pages 1053-1055 | Published online: 09 Jan 2014

References

  • Quaranta D, Marra C, Zinno M et al. Presentation and validation of the Multiple Sclerosis Depression Rating Scale: a test specifically devised to investigate affective disorders in multiple sclerosis patients. Clin. Neuropsychol. 26(4), 571–587 (2012).
  • Nyenhuis DL, Rao SM, Zajecka JM, Luchetta T, Bernardin L, Garron DC. Mood disturbance versus other symptoms of depression in multiple sclerosis. J. Int. Neuropsychol. Soc. 1(3), 291–296 (1995).
  • Chang CH, Nyenhuis DL, Cella D, Luchetta T, Dineen K, Reder AT. Psychometric evaluation of the Chicago Multiscale Depression Inventory in multiple sclerosis patients. Mult. Scler. 9(2), 160–170 (2003).
  • Patten SB, Fridhandler S, Beck CA, Metz LM. Depressive symptoms in a treated multiple sclerosis cohort. Mult. Scler. 9(6), 616–620 (2003).
  • Kroenke K, Spitzer RL, Williams JB, Löwe B. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. Gen. Hosp. Psychiatry 32(4), 345–359 (2010).
  • Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 6(4), 278–296 (1967).
  • Potts MK, Daniels M, Burnam MA, Wells KB. A structured interview version of the Hamilton Depression Rating Scale: evidence of reliability and versatility of administration. J. Psychiatr. Res. 24(4), 335–350 (1990).
  • Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65(9), 732–741 (2009).
  • Zabad RK, Patten SB, Metz LM. The association of depression with disease course in multiple sclerosis. Neurology 64(2), 359–360 (2005).
  • Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 344(13), 961–966 (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.